Rotation to methadone as a second-line opioid may be safe and efficacious when using a tiered scheme with close follow-up in patients with cancer who experience pain, according to a study published in The Oncologist.1

Researchers led by Josep Porta-Sales, MD, PhD, of the Institut Català d’Oncologia in Spain, conducted a prospective, open-label study of 145 patients whose treatment was rotated from opioids to methadone, with the main outcome being change in the variable “worst pain” at day 28. Levels of pain were examined at study entry as well as at days 3, 7, 9, 14, 21, and 28.

Pain and pain interference were measured using the Brief Pain Inventory; side effects were evaluated according to the Common Terminology Criteria for Adverse Events version 3.0.

The researchers found that reasons for rotation to methadone included poor pain control in (77.9% of patients), opioid side effects (2.1%), or both (20%). Mean daily oral morphine-equivalent dose before rotation was 193.7 mg.

Median worst and average pain scores decreased significantly from baseline to day 28, from 9 to 6, while the median average pain score decreased from 6 to 4.

RELATED: ASCO Issues Policy Statement on Curbing Abuse of Opioids

By day 28, the proportion of patients with moderate to severe worst pain decreased by 30.3%. Average pain decreased by 47.5%.

“These findings corroborate previously reported outcomes in retrospective outpatient studies and prospective studies that evaluated inpatient populations,” the authors concluded.

Reference

  1. Sales-Porta J, Garzón-Rodríguez C, Villavicencio-Chávez C, Llorens-Torromé S, González-Barboteo J. Efficacy and safety of methadone as a second-line opioid for cancer pain in an outpatient clinic: a prospective open-label study [published online ahead of print June 15, 2016.] Oncologist. doi: 10.1634/theoncologist.2015-0503.